172 related articles for article (PubMed ID: 26829942)
41. Practical issues in handling data input and uncertainty in a budget impact analysis.
Nuijten MJ; Mittendorf T; Persson U
Eur J Health Econ; 2011 Jun; 12(3):231-41. PubMed ID: 20364289
[TBL] [Abstract][Full Text] [Related]
42. Assessing new health technologies: lessons to be learned from drugs.
Henry DA; Hill SR
Med J Aust; 1999 Nov; 171(10):554-6. PubMed ID: 10816710
[TBL] [Abstract][Full Text] [Related]
43. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
Masucci L; Beca J; Sabharwal M; Hoch JS
Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
[TBL] [Abstract][Full Text] [Related]
44. [Involving patients in the evaluation of health technologies at the French National Authority for Health (HAS)].
Nabarette H
Sante Publique; 2018; 30(6):767-775. PubMed ID: 30990265
[TBL] [Abstract][Full Text] [Related]
45. Medical devices and pharmaceuticals: differences in public acceptance.
Holmes DR; Wood DL
Am Heart Hosp J; 2006; 4(4):269-72. PubMed ID: 17086007
[TBL] [Abstract][Full Text] [Related]
46. Na domhain shamhlaíochta: formulary submission guidelines in Ireland and the standards of normal science.
Langley PC
Curr Med Res Opin; 2016 Oct; 32(10):1641-1644. PubMed ID: 27181031
[TBL] [Abstract][Full Text] [Related]
47. [Medico-economic evaluation. Good practices and methodology in the study of drugs].
Lanoe JL; Flahaut MA; Legrain M
Therapie; 1993; 48(4):303-6. PubMed ID: 7907439
[No Abstract] [Full Text] [Related]
48. [The Exploration of Extrapolation of Data from Adults to Pediatric Population].
Liu L; Cui X; Zhang Y; Xu W
Zhongguo Yi Liao Qi Xie Za Zhi; 2019 Sep; 43(5):375-378. PubMed ID: 31625341
[TBL] [Abstract][Full Text] [Related]
49. ECJ/ 2013/ 12 - European Commission v. Kingdom of Spain, 17 January 2013 (C-360/11).
Baeyens A; Goffin T
Eur J Health Law; 2013 Apr; 20(2):221-5. PubMed ID: 23772468
[No Abstract] [Full Text] [Related]
50. Clinical laboratory equipment manufacturers' lack of guidance for high consequence pathogen response is a critical weakness.
Le AB; Figi CE; Herstein JJ; Iwen PC; Buehler SA; Lowe JJ; Gibbs SG
Infect Control Hosp Epidemiol; 2024 Mar; ():1-3. PubMed ID: 38525674
[No Abstract] [Full Text] [Related]
51. The Pharmaceutical Manufacturers' View of Health Insurance.
Can Med Assoc J; 1944 Mar; 50(3):255. PubMed ID: 20323037
[No Abstract] [Full Text] [Related]
52. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Aug; 90(8):089501. PubMed ID: 31472613
[TBL] [Abstract][Full Text] [Related]
53. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Sep; 90(9):099501. PubMed ID: 31575255
[TBL] [Abstract][Full Text] [Related]
54. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Nov; 90(11):119501. PubMed ID: 31779438
[TBL] [Abstract][Full Text] [Related]
55. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Dec; 90(12):129501. PubMed ID: 31893809
[TBL] [Abstract][Full Text] [Related]
56. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Jan; 90(1):019501. PubMed ID: 30709162
[TBL] [Abstract][Full Text] [Related]
57. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2020 Jan; 91(1):015111. PubMed ID: 32012516
[TBL] [Abstract][Full Text] [Related]
58. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Feb; 90(2):029501. PubMed ID: 30831727
[TBL] [Abstract][Full Text] [Related]
59. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2020 Feb; 91(2):029501. PubMed ID: 32113409
[TBL] [Abstract][Full Text] [Related]
60. Review of Scientific Instruments New Products.
Mandelis A
Rev Sci Instrum; 2019 Mar; 90(3):039501. PubMed ID: 30927794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
